{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:16Z","timestamp":1790803696106,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ZEMANI17K0"],"award-info":[{"award-number":["ZEMANI17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HAMBLE17K0"],"award-info":[{"award-number":["HAMBLE17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 DK 089507"],"award-info":[{"award-number":["P30 DK 089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002535"],"award-info":[{"award-number":["UL1 TR002535"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:24:26Z","timestamp":1707967466000},"page":"676-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-9337","authenticated-orcid":false,"given":"E.T.","family":"Zemanick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Emerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-460X","authenticated-orcid":false,"given":"M.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-6018","authenticated-orcid":false,"given":"M.N.","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2571","authenticated-orcid":false,"given":"K.","family":"Odem-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"D.R.","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-0644","authenticated-orcid":false,"given":"C.L.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"M.W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jcf.2024.02.001_bib0001","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMc1502191","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.02.001_bib0002","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.001_bib0003","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","article-title":"Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype","volume":"14","author":"McKone","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.jcf.2024.02.001_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2024.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.001_bib0006","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2023.02.012","article-title":"When triple therapy is not working: a reverse iceberg perspective","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.001_bib0007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.001_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcf.2022.07.008","article-title":"Characterizing CFTR modulated sweat chloride response across the cf population: initial results from the CHEC-SC study","volume":"22","author":"Mayer-Hamblett","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.001_bib0009","series-title":"R: a language and environment for statistical computing","year":"2023"},{"key":"10.1016\/j.jcf.2024.02.001_bib0010","series-title":"All of nonparametric statistics","author":"Wasserman","year":"2006"},{"key":"10.1016\/j.jcf.2024.02.001_bib0011","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis. New York, NY: Springer-Verlag New York; 2016."},{"key":"10.1016\/j.jcf.2024.02.001_bib0012","unstructured":"Larsson J. eulerr: area-Proportional Euler and Venn Diagrams with Ellipses. 2022."},{"issue":"6","key":"10.1016\/j.jcf.2024.02.001_bib0013","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jcf.2024.02.001_bib0014","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.001_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcf.2017.11.002","article-title":"The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype","volume":"17","author":"Espel","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.001_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.12-1430","article-title":"Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience","volume":"143","author":"Durmowicz","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.001_bib0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV(1) in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.001_bib0018","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.02.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.001_bib0021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcf.2022.02.001","article-title":"How the sweat gland reveals levels of CFTR activity","volume":"21","author":"Wine","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.001_bib0022","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jcf.2022.09.011","article-title":"ECFS standards of care on CFTR-related disorders: updated diagnostic criteria","volume":"21","author":"Castellani","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.001_bib0023","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jcf.2022.09.005","article-title":"ECFS standards of care on CFTR-related disorders: diagnostic criteria of CFTR dysfunction","volume":"21","author":"Sermet-Gaudelus","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:08:49Z","timestamp":1783019329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000158"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}